Earnings ·
Rhythm Pharmaceuticals reports $71.3 million in Q2 IMCIVREE revenue, up 19% sequentially
RYTMRhythm Pharmaceuticals, Inc.
On August 4, 2026, Rhythm Pharmaceuticals reported second quarter 2026 financial results and business updates. Net product revenue from global sales of IMCIVREE reached $71.3 million, a 19% sequential increase driven by U.S. sales of $51.0 million following the March FDA approval for acquired hypothalamic obesity (HO). The company received more than 400 patient start forms from approximately 300 prescribers since approval. Rhythm reported a net loss attributable to common stockholders of $(50.4) million, or $(0.73) per share, compared to $(48.0) million in the prior year period. Cash and short-term investments stood at $330.9 million as of June 30, 2026. The company also announced preliminary Phase 2 data for investigational drug RM-718 in acquired HO patients, showing an 11.6% mean BMI reduction at 16 weeks with a favorable safety profile regarding hyperpigmentation. Rhythm operates as a commercial-stage biopharmaceutical company focused on treating rare neuroendocrine diseases.